Global MSK Sirtex Medical is actively involved in international markets with offices in the U.S., Australia, Germany, and Singapore, and has delivered over 150K doses across 50+ countries, indicating a broad global footprint and potential for regional partnerships and distribution expansion.

Liver Cancer Focus The flagship SIR-Spheres Y-90 resin microspheres target liver cancer, presenting a clear cross-sell opportunity with interventional radiology and oncology practices seeking targeted radiation therapies.

Expansion & Innovation Recent launches such as the SIROS Delivery System and the LAVA Liquid Embolic System, along with EU certification, suggest ongoing product modernization and potential for expanded sales to interventional suites and hospitals.

Strategic Partnerships Collaborations with Magle Group and participation in MSK embolization forums indicate openness to channel partnerships, co-marketing, and joint-education programs to reach surgeons and interventional teams.

Growth Readiness Revenue scale ($100M–$250M) and a sizable employee base (201–500) imply capacity for scaling field sales, clinical education teams, and after-sales support to support broader adoption and training.